Tags

Type your tag names separated by a space and hit enter

Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.
Nutr Res. 2012 Sep; 32(9):701-8.NR

Abstract

Obesity is associated with a markedly increased risk of nonalcoholic fatty liver disease. The anti-inflammatory polyphenol resveratrol possess promising properties in preventing this metabolic condition by dampening the pathological inflammatory reaction in the hepatic tissue. However, in the current study, we hypothesize that the beneficial effect of resveratrol is not solely attributable to its anti-inflammatory potential. Eight-week-old male Wistar rats were randomly distributed into 3 groups of 12 animals each: control diet (C), high-fat diet (HF), and HF supplemented with 100 mg resveratrol daily (HFR). After 8 weeks of dietary treatment, the rats were euthanized and relevant tissues were prepared for subsequent analysis. Resveratrol prevented the high fat-induced steatosis assessed by semiquantitative grading, which furthermore corresponded with a complete normalization of the hepatic triglyceride content (P < .001), despite no change in total body fat. In HFR, the hepatic uncoupling protein 2 expression was significantly increased by 76% and 298% as compared with HF and C, respectively. Moreover, the hepatic mitochondria content in HFR was significantly higher as compared with both C and HF (P < .001 and P = .004, respectively). We found no signs of hepatic inflammation, hereby demonstrating that resveratrol protects against fatty liver disease independently of its proposed anti-inflammatory potential. Our data might indicate that an increased number of mitochondria and, particularly, an increase in hepatic uncoupling protein 2 expression are involved in normalizing the hepatic fat content due to resveratrol supplementation in rodents fed a high-fat diet.

Authors+Show Affiliations

Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Århus C, Denmark. mmp@ki.au.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23084643

Citation

Poulsen, Morten Møller, et al. "Resveratrol Up-regulates Hepatic Uncoupling Protein 2 and Prevents Development of Nonalcoholic Fatty Liver Disease in Rats Fed a High-fat Diet." Nutrition Research (New York, N.Y.), vol. 32, no. 9, 2012, pp. 701-8.
Poulsen MM, Larsen JØ, Hamilton-Dutoit S, et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res. 2012;32(9):701-8.
Poulsen, M. M., Larsen, J. Ø., Hamilton-Dutoit, S., Clasen, B. F., Jessen, N., Paulsen, S. K., Kjær, T. N., Richelsen, B., & Pedersen, S. B. (2012). Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutrition Research (New York, N.Y.), 32(9), 701-8. https://doi.org/10.1016/j.nutres.2012.08.004
Poulsen MM, et al. Resveratrol Up-regulates Hepatic Uncoupling Protein 2 and Prevents Development of Nonalcoholic Fatty Liver Disease in Rats Fed a High-fat Diet. Nutr Res. 2012;32(9):701-8. PubMed PMID: 23084643.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. AU - Poulsen,Morten Møller, AU - Larsen,Jens Ø, AU - Hamilton-Dutoit,Stephen, AU - Clasen,Berthil F, AU - Jessen,Niels, AU - Paulsen,Søren K, AU - Kjær,Thomas N, AU - Richelsen,Bjørn, AU - Pedersen,Steen B, Y1 - 2012/09/25/ PY - 2012/05/10/received PY - 2012/07/18/revised PY - 2012/08/06/accepted PY - 2012/10/23/entrez PY - 2012/10/23/pubmed PY - 2013/3/27/medline SP - 701 EP - 8 JF - Nutrition research (New York, N.Y.) JO - Nutr Res VL - 32 IS - 9 N2 - Obesity is associated with a markedly increased risk of nonalcoholic fatty liver disease. The anti-inflammatory polyphenol resveratrol possess promising properties in preventing this metabolic condition by dampening the pathological inflammatory reaction in the hepatic tissue. However, in the current study, we hypothesize that the beneficial effect of resveratrol is not solely attributable to its anti-inflammatory potential. Eight-week-old male Wistar rats were randomly distributed into 3 groups of 12 animals each: control diet (C), high-fat diet (HF), and HF supplemented with 100 mg resveratrol daily (HFR). After 8 weeks of dietary treatment, the rats were euthanized and relevant tissues were prepared for subsequent analysis. Resveratrol prevented the high fat-induced steatosis assessed by semiquantitative grading, which furthermore corresponded with a complete normalization of the hepatic triglyceride content (P < .001), despite no change in total body fat. In HFR, the hepatic uncoupling protein 2 expression was significantly increased by 76% and 298% as compared with HF and C, respectively. Moreover, the hepatic mitochondria content in HFR was significantly higher as compared with both C and HF (P < .001 and P = .004, respectively). We found no signs of hepatic inflammation, hereby demonstrating that resveratrol protects against fatty liver disease independently of its proposed anti-inflammatory potential. Our data might indicate that an increased number of mitochondria and, particularly, an increase in hepatic uncoupling protein 2 expression are involved in normalizing the hepatic fat content due to resveratrol supplementation in rodents fed a high-fat diet. SN - 1879-0739 UR - https://www.unboundmedicine.com/medline/citation/23084643/Resveratrol_up_regulates_hepatic_uncoupling_protein_2_and_prevents_development_of_nonalcoholic_fatty_liver_disease_in_rats_fed_a_high_fat_diet_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0271-5317(12)00165-0 DB - PRIME DP - Unbound Medicine ER -